ABL Bio Inc. (298380.KQ)
- Previous Close
66,100.00 - Open
0.00 - Bid --
- Ask --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 74,100.00 - Volume
0 - Avg. Volume
1,390,269 - Market Cap (intraday)
3.152T - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Aug 11, 2025 - Aug 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
70,000.00
ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is headquartered in Seongnam-si, South Korea.
www.ablbio.comRecent News: 298380.KQ
View MorePerformance Overview: 298380.KQ
Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 298380.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 298380.KQ
View MoreValuation Measures
Market Cap
3.18T
Enterprise Value
3.11T
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
115.20
Price/Book (mrq)
22.66
Enterprise Value/Revenue
111.82
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-259.52%
Return on Assets (ttm)
-26.36%
Return on Equity (ttm)
-69.34%
Revenue (ttm)
27.63B
Net Income Avi to Common (ttm)
-71.71B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
108.57B
Total Debt/Equity (mrq)
30.30%
Levered Free Cash Flow (ttm)
-68.61B